-
Metal-Ion-Chelating l-Phe Nanostructures Enhance ICB
2026-09-07
This Nature Nanotechnology study shows that metal-ion-chelating l-phenylalanine nanostructures can remodel immunosuppressive breast and colorectal tumour microenvironments and improve immune checkpoint blockade responses. Its central innovation is the use of electrophysiological modulation, inflammasome signaling, and short-term starvation to activate dendritic cells and strengthen tumour-specific cytotoxic T-cell immunity.
-
7-dehydro Cholesterol: Workflow & Applications
2026-09-05
Use 7-dehydro Cholesterol to connect DHCR7 activity with sterol flux, UVB-driven vitamin D3 formation, oxidation, and immune phenotypes. This practical guide translates a 2026 dhcr7 knockout grass carp study into assay design, controls, optimization steps, and troubleshooting decisions.
-
LSKL Reduces Oxidative Stress in a PCOS Model
2026-09-04
The reference study identifies THBS1 inhibition by LSKL as a potential mechanism for reducing DHEA-induced oxidative stress and apoptosis in rat granulosa cells. By combining molecular docking, cellular assays, and a rat model, it links ovarian protection with restoration of PI3K/AKT signaling, improved hormone balance, and recovery of ovarian morphology.
-
Risedronate Sodium: FPP Synthase Inhibitor Workflows
2026-09-04
Risedronate Sodium enables mechanism-led studies of osteoclast activity, bone remodeling, delivery systems, and exploratory tumor-cell phenotypes. This workflow-focused guide connects FPPS inhibition with practical dosing, assay design, formulation handling, and troubleshooting across bone and lung research.
-
Parathyroid hormone (1-34) (human): Mechanism
2026-09-03
Parathyroid hormone (1-34) (human) is a defined PTH (1-34) peptide fragment that activates calcium-regulatory signaling and supports bone metabolism research. Its receptor-binding, cAMP, solubility, storage, and in vivo bone-mass benchmarks are product-specific measurements and should not be interpreted as clinical dosing guidance.
-
FGFR–TGFβ–PI3K/AKT Control of Periostin
2026-09-03
Labrèche et al. identified a pathway cross talk that controls periostin expression in Neu-positive breast cancer cells, linking FGF/FGFR, TGFβ, PKC, and PI3K/AKT signaling. The study helps explain how epithelial tumor cells acquire periostin expression and provides a framework for interpreting tumor-cell and stromal contributions to the breast cancer microenvironment.
-
Vitamin C in Senescence and Cancer Workflows
2026-09-02
Discover how Vitamin C and ascorbic acid can be deployed in oxidative-stress, cellular-senescence, and cancer research workflows. This guide connects a D-galactose-induced HEI-OC1 model with practical assay design, dose selection, controls, and troubleshooting for reproducible results.
-
Dynasore: Practical Workflow for Endocytosis Studies
2026-09-02
Dynasore is a cell-permeable dynamin GTPase inhibitor for reversible, dose-dependent perturbation of dynamin-dependent endocytosis and vesicle trafficking. It is useful for controlled cellular pathway studies, but should not be treated as a dynamin1, dynamin2, or Drp1-specific probe or as evidence of therapeutic activity.
-
Humanized Mice Improve CES Prodrug PK Prediction
2026-09-01
This 2025 study shows that humanized-liver mice can reduce species-related uncertainty when evaluating the carboxylate ester prodrug HD56 and its active metabolite HD561. By integrating transporter, enzyme, microsomal, plasma, and pharmacokinetic experiments, the authors establish a strong in vivo–in vitro correlation that supports more human-relevant prodrug development.
-
MK-571: From Airway Signaling to Translational Insight
2026-09-01
MK-571 (L-660,711) is best understood as a mechanistic bridge between cysteinyl leukotriene receptor biology and MRP1/ABCC1-mediated transport. This thought-leadership guide shows translational researchers how to use the compound in airway, macrophage, and cytotoxicity assays while avoiding pathway misattribution.
-
Pronase E Workflows for TNBC Proteomics
2026-08-31
Learn how Pronase E supports broad protein digestion, peptide mapping, and proteomics workflows connected to the CUL3–MTDH ferroptosis axis in triple-negative breast cancer research. The article emphasizes practical assay design, fresh-solution handling, comparative digestion strategies, and troubleshooting rather than treating a sample-preparation enzyme as a therapeutic agent.
-
Leucomycin (Kitasamycin): Assay Workflows
2026-08-31
Leucomycin (kitasamycin) supports more than routine antimicrobial screening: it connects bacterial growth inhibition assays with translational inhibition studies and macrolide resistance characterization. This practical guide covers solvent handling, MIC workflows, comparative testing, resistance analysis, and interpretation of isolate-specific efficacy.
-
BRD4–RAC1 Co-targeting in Breast Cancer
2026-08-30
The 2021 International Journal of Biological Sciences study shows that simultaneous inhibition of BET bromodomain BRD4 and RAC1 suppresses growth, stemness, migration, and xenograft tumorigenesis across breast cancer subtypes. Its mechanistic contribution is to connect BRD4–RAC1 inhibition with disruption of the c-MYC–G9a–FTH1 axis and downregulation of HDAC1, providing a rationale for combination rather than single-pathway targeting.
-
PPARG R212W in Familial Partial Lipodystrophy Type 3
2026-08-29
This 2026 study links the PPARG R212W variant to familial partial lipodystrophy type 3 through reduced receptor activity, accelerated protein degradation, mitochondrial dysfunction, and impaired adipocyte gene expression. Partial rescue by rosiglitazone supports ligand-based functional testing while highlighting the need to distinguish molecular rescue from clinical efficacy.
-
Verapamil Targets TXNIP in Osteoporosis Research
2026-08-28
A 2025 Journal of Orthopaedic Translation study identifies TXNIP as a mechanistic link between verapamil exposure and reduced bone loss in ovariectomized mice. By combining human genetic association data, cell-based assays, transcriptomics, and in vivo imaging, the work supports further investigation of verapamil-driven regulation of osteoclast and osteoblast activity while leaving clinical efficacy and dosing unresolved.